TRNLY yields 95.24% · JNJ yields 2.13%● Live data
📍 TRNLY pulled ahead of the other in Year 1
Combined, TRNLY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TRNLY + JNJ for your $10,000?
The Trendlines Group Ltd. is an innovation commercialization company and a private equity and venture capital firm specializing in incubation, seed, start-up, early venture and late venture investments. The firm seeks to invest in food, clean technology, agritechnology, lifesciences with a focus on medical devices, biotechnology, and pharmaceuticals, security, medical, and information technology companies. It considers investments in Israel and Singapore. The firm offers business incubation, partner and channel development, market strategies, business plans, research and development and commercialization activities, business development, finance and funding strategies, administrative services and marketing communications services to entrepreneurs. The firm seeks to invest a minimum of $0.06 million in its portfolio companies. The firm prefers to exit its investments through merger and acquisition transactions, listing on public stock exchanges, or other dispositions of holdings. It leverages its own capital with government funding to mitigate risk in creating and developing new businesses. It is involved in all aspects of its portfolio companies from technology development to business building. The Trendlines Group Ltd. was founded in 1993 and is based in M.P. Misgav, Israel with additional offices in Tel Aviv, Israel; Beijing, China; and Singapore, Singapore.
Full TRNLY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.